• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aligos Therapeutics Inc (NQ: ALGS )

    9.780 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Aligos Therapeutics Inc

    < Previous 1 2 3 4 5 6 Next >
    Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2023 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Announce Second Quarter Results on August 03, 2023
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Announces the Selection of Stephen Harrison, MD as Principal Investigator of Ph2a Study and Key Study Design Elements/Milestones for NASH Drug Candidate, ALG-055009
    From Aligos Therapeutics
    Via GlobeNewswire
    Recap: Aligos Therapeutics Q1 Earnings
    Via Benzinga
    Aligos Therapeutics Earnings Preview
    Via Benzinga
    Aligos Therapeutics Earnings Perspective: Return On Capital Employed
    Via Benzinga
    A Preview Of Aligos Therapeutics's Earnings
    Via Benzinga
    Aligos Therapeutics Presents Data from its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Present Data on its Liver Disease Programs at the European Association for the Study of the Liver (EASL) Congress 2023
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Present at the Jefferies 2023 Healthcare Conference
    From Aligos Therapeutics
    Via GlobeNewswire
    Week In Review: LaNova Sells Pre-Clinical ADC To AstraZeneca In $600 Million Deal
    LaNova Medicines has sold global rights for a pre-clinical antibody drug conjugate candidate to AstraZeneca for $600 million, including $55 million upfront plus royalties on sales. Meanwhile, Amoytop... 
    Via Talk Markets
    Why Venus Concept Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Gainers NeoGames S.A. (NASDAQ: NGMS) shares climbed 113.3% to $27.38 as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why NeoGames Shares Are Trading Higher By 121%; Here Are 20 Stocks Moving Premarket
    Gainers NeoGames S.A. (NASDAQ: NGMS) shares surged 121% to $28.38 in pre-market trading as the company agreed to be acquired by Aristocrat Leisure Limited for $29.50 per share in cash. 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    We're starting off the week with a breakdown of the biggest pre-market stock movers worth keeping an eye on Monday morning! 
    Via InvestorPlace
    Aligos Therapeutics Announces Research Collaboration and Development Agreement with Xiamen Amoytop Biotech Co. Ltd. for Use of Aligos’ Oligonucleotide Platform for the Treatment of Liver Diseases
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Announce First Quarter Results on May 4, 2023
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Present Data from Chronic Hepatitis B and Hepatocellular Carcinoma Programs at the European Association for the Study of the Liver (EASL) Congress 2023
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Presents Clinical Data from NASH Program at the 2023 Paris Hepatology Conference
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Therapeutics to Present at the SVB Securities Global Biopharma Conference
    From Aligos Therapeutics
    Via GlobeNewswire
    Aligos Reprioritizes Pipeline With Focus On NASH, COVID Programs, Cuts Another 10% Of Its Workforce
    Via Benzinga
    Aligos Therapeutics Announces Strategic Reprioritization of NASH and COVID-19 Programs and Confirms Key Timelines and Extension of Cash Runway to Year-End 2024
    From Aligos Therapeutics
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program... 
    Via Benzinga
    Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
    Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.